Company Dossier · Health Care
Centene Corporation
- S&P 500
- Russell 1000
What Centene Corporation is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $179 billion, up 13% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $8.95 billion, up 729% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.80 billion, up 23% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $0.48 billion.SEC EDGAR filings (10-K)
- Long-term debt issued in the fiscal year to December 31, 2025: $0.75 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (July 28, 2026): sentiment 0.70 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.80 of 1.Palanor Discourse
- Guidance in the last 90 days: 6 outlook figures raised, 3 lowered, 0 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 17, 2026): 0 risk factors added, 1 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $6.9 million on the open market.SEC Form 4
- 1,007 institutional managers reported a position at June 30, 2026 (+140 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 34 (36 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →What Centene Corporation is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Steady · Confident
Expanding ↔ Retrenching
Steady
- Capital spending85th pct
- Debt raised10th pct
- Buybacks vs capex97th pct
- Hiring filings15th pct
- Deals and private raises49th pct
- Patent publications94th pct
Confident ↔ Hedging
Confident
- Call sentiment81st pct
- Call confidence64th pct
- Guidance changes72nd pct
- Risk factors added84th pct
- Insider open-market trades29th pct
- + Call sentiment
- + Guidance changes
- + Risk factors added
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver5th pct
- Stress filings48th pct
Credit
How these are built →Centene Corporation's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$16.1B
- Due within a year $0.1B
- Longer term $16.0B
- Default point $8.1B (short + ½ long)
Finance leases included · Jun 30, 2026 filing
Bonds priced, last 12 months
None
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
In the news
Headlines that name Centene Corporation, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralCentene Q3 2026 Preview: The Quarter Is Easy, The 2027 Bridge Is Not (NYSE:CNC)
seekingalpha.com · via Marketaux · Oct 10, 2026
- NeutralCentene Corp (CNC) Stock Up 3.3% and Still Undervalued -- GF Score: 71/100
gurufocus.com · via Marketaux · Oct 2, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026LobbyingLobbying report (BGR GOVERNMENT AFFAIRS)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (WILLIAMS AND JENSEN, PLLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (CENTENE CORPORATION)third_quarter 2026 · $1.1 million
- Oct 19, 2026LobbyingLobbying report (CONTINENTAL STRATEGY, LLC)third_quarter 2026 · $0.1 million
- Oct 17, 2026LobbyingLobbying report (BROWNSTEIN HYATT FARBER SCHRECK, LLP)third_quarter 2026 · $0.1 million
- Aug 17, 20268-KDirector or officer changeItem 5.02
- Jul 28, 20268-KDirector or officer changeItem 5.02
- Jul 20, 2026LobbyingLobbying report (BGR GOVERNMENT AFFAIRS)second_quarter 2026 · $0.1 million
- Jul 20, 2026LobbyingLobbying report (WILLIAMS AND JENSEN, PLLC)second_quarter 2026 · $0.1 million
- Jul 20, 2026LobbyingLobbying report (CENTENE CORPORATION)second_quarter 2026 · $1.5 million
- Jun 22, 20268-KDirector or officer changeItem 5.02
- May 15, 20268-KDirector or officer changeItem 5.02
- May 15, 20268-KShareholder vote resultsItem 5.07
- Apr 21, 2026Trademark
- Mar 24, 20268-KDirector or officer changeItem 5.02
- Feb 17, 202610-KAnnual report (10-K)0 risk factors added, 1 removed
- Jan 8, 2026Trademark
- Jan 6, 2026Patent
- Dec 23, 2025Trademark
- Aug 18, 2025Trademark
- Aug 18, 2025Trademark
- Aug 15, 20258-KDirector or officer changeItem 5.02
- Aug 4, 20258-KDirector or officer changeItem 5.02
- May 14, 20258-KShareholder vote resultsItem 5.07
- Mar 5, 20258-KMaterial agreement signedItem 1.01
- Mar 5, 20258-KMaterial agreement terminatedItem 1.02
- Feb 24, 20258-KDirector or officer changeItem 5.02
- Feb 18, 202510-KAnnual report (10-K)2 risk factors added, 0 removed
- Nov 12, 20248-KDirector or officer changeItem 5.02
- Feb 20, 202410-KAnnual report (10-K)3 risk factors added, 3 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Elevance Health ELV | $201B | $6.3B | Jun 30, 2026 |
| Humana HUM | $137B | $1.3B | Mar 31, 2026 |
| Molina Healthcare MOH | $44.5B | −$0.6B | Jun 30, 2026 |
| Cardinal Health CAH | $245B | $5.5B | Dec 31, 2025 |
| Cigna CI | $282B | — | Jun 30, 2026 |
| Johnson & Johnson JNJ | $97.9B | $22.2B | Jun 28, 2026 |
| Cencora COR | $333B | $4.1B | Jun 30, 2026 |
| Eli Lilly and Company LLY | $79.7B | — | Jun 30, 2026 |